Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Infliximab is an IgG1 antitumor necrosis factor monoclonal antibody that is commonly used to treat inflammatory bowel disease (IBD) and other autoimmune disorders. However, it is known to increase the risk of reactivation of latent tuberculosis (LTBI) due to its capability to disrupt TB granulomas. We describe a case of extrapulmonary TB in a patient with ulcerative colitis who was treated with Infliximab after a negative Quantiferon Test. In addition, we report briefly on the current controversy about the appropriateness, interval, and methods for the repeated screening of latent TB in IBD patients that are treated with antitumor necrosis factor alpha (TNF-α) antibodies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145928 | PMC |
| http://dx.doi.org/10.3390/pathogens10050535 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Blood proteomic signatures associated with disease activity in Inflammatory Bowel Diseases.
J Crohns Colitis
September 2025
Université de Paris, INSERM U1342, Institut de Recherche Saint-Louis, Paris, France.
Background And Aims: Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), remain heterogeneous disorders with variable response to biologics. Post-operative recurrence in CD is common despite surgery and prophylactic biotherapies. Understanding the inflammatory mediators associated with recurrence and treatment response could pave the way for personalized strategies.
View Article and Find Full Text PDFPrimary Sclerosing Cholangitis Worsens Prognosis in Patients With Inflammatory Bowel Disease: A Propensity-Matched Cohort Study.
United European Gastroenterol J
September 2025
Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita Salute San Raffaele University, Milan, Italy.
Background: Few data are available on the impact of primary sclerosing cholangitis (PSC) on inflammatory bowel disease (IBD).
Objective: We conducted a retrospective study using TriNetX to compare the outcomes of patients with IBD and those with concomitant IBD and PSC.
Methods: All patients with a confirmed diagnosis of Crohn's disease (CD), ulcerative colitis (UC), or indeterminate colitis with or without PSC were eligible.
Durable Long-Term Outcomes After Early Transcatheter Arterialization of the Deep Veins.
JACC Case Rep
September 2025
University Hospitals Harrington Heart & Vascular Institute, Cleveland, Ohio, USA. Electronic address:
Background: Up to 20% of patients with chronic limb-threatening ischemia (CLTI) are not eligible for conventional revascularization options despite having severe symptoms of nonhealing ulcers and gangrene. Transcatheter arterialization of the deep veins (TADV) has shown promising results in this challenging subset of patients.
Case Summary: We present the long-term outcomes of 4 patients with no-option CLTI who were at risk of major below-the-knee amputation and were treated with TADV with the LimFlow System (Inari Medical).
Inflammatory-Driven Vitamin A Transport Dysfunction in Ulcerative Colitis.
Int J Vitam Nutr Res
September 2025
Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, 300070 Tianjin, China.
Background: Retinol-binding protein 4 (RBP4) is a vitamin A transport protein synthesized in the liver and also plays a crucial role in inflammation and immune regulation. Low serum vitamin A levels have been observed in both pediatric and adult patients with ulcerative colitis (UC). The association between serum vitamin A levels and serum RBP4 levels, as well as the underlying mechanism involved inimpaired vitamin A transport during inflammation in UC patients, has yet to been investigated.
View Article and Find Full Text PDFTherapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease: A Nationwide Survey of Anti-TNF Therapy Practices, Attitudes, and Barriers.
Crohns Colitis 360
July 2025
James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Background: Proactive therapeutic drug monitoring (TDM) for tumor necrosis factor alpha antagonist (anti-TNF) therapy in adult inflammatory bowel disease (IBD) remains controversial, with inconsistent findings from clinical trials and meta-analyses. Pediatric societal guidelines endorse the implementation of proactive TDM. However, the integration of TDM into clinical practice by pediatric gastroenterologists has not been characterized.
View Article and Find Full Text PDF